Trulieve Cannabis Corp. Subordi (TRLV) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.11
- Estimate
- $0.03
- Surprise
- +266.7%
- Revenue (period 2026-06-30)
- $271.0M
- Score at report (before → after)
- 5.8 → 5.7/10
Revenue source: xbrl.
How the report landed
Trulieve Cannabis Corp. Subordi (TRLV) beat the $0.03 estimate with diluted EPS of $0.11 — a large 266.7% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.8/10) to Hold at 5.7/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates TRLV Sell at 5.5/10.
2 of the last 4 quarters beat the estimate; this quarter's +266.7% surprise compares with a +148.6% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Attractive valuation
What argues against it
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7)
- Negative momentum
- Momentum score 3.7/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $11.64
- Price target
- $15.82
- Stop
- $10.74
- Upside to target
- +35.9%
- Reward-to-risk
- 2.5:1
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
TRLV at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $2.23B
- P/E (fwd)
- 20.8
- 52-week range
- $4.62–$13.28
- Off 52-week high
- 12.3%
- RSI (14)
- 51
- Volume vs avg
- 1.03×
- Score today
- 5.5/10